Thrombolysis in ischemic stroke: Focus on new treatment strategies

Research output: Contribution to journalArticle

Abstract

Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.

Original languageEnglish
Pages (from-to)42-52
Number of pages11
JournalRecent Patents on Cardiovascular Drug Discovery
Volume7
Issue number1
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Stroke
Fibrinolytic Agents
Patents
Cerebral Hemorrhage
Tissue Plasminogen Activator
Reperfusion
Cause of Death
Therapeutics

Keywords

  • Bridging
  • Intra-arterial thrombolysis
  • Intravenous thrombolysis
  • Mechanical clot retrieval
  • Patents thrombolytic agents
  • Rtpa
  • Sonothrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Thrombolysis in ischemic stroke : Focus on new treatment strategies. / Calabrò, Rocco S.; Gervasi, Giuseppe; Bramanti, Placido; Cavallini, Anna.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 7, No. 1, 04.2012, p. 42-52.

Research output: Contribution to journalArticle

@article{6043f5241671427c8cd618b5d045467d,
title = "Thrombolysis in ischemic stroke: Focus on new treatment strategies",
abstract = "Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.",
keywords = "Bridging, Intra-arterial thrombolysis, Intravenous thrombolysis, Mechanical clot retrieval, Patents thrombolytic agents, Rtpa, Sonothrombolysis",
author = "Calabr{\`o}, {Rocco S.} and Giuseppe Gervasi and Placido Bramanti and Anna Cavallini",
year = "2012",
month = "4",
doi = "10.2174/157489012799362412",
language = "English",
volume = "7",
pages = "42--52",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Thrombolysis in ischemic stroke

T2 - Focus on new treatment strategies

AU - Calabrò, Rocco S.

AU - Gervasi, Giuseppe

AU - Bramanti, Placido

AU - Cavallini, Anna

PY - 2012/4

Y1 - 2012/4

N2 - Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.

AB - Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.

KW - Bridging

KW - Intra-arterial thrombolysis

KW - Intravenous thrombolysis

KW - Mechanical clot retrieval

KW - Patents thrombolytic agents

KW - Rtpa

KW - Sonothrombolysis

UR - http://www.scopus.com/inward/record.url?scp=84857712697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857712697&partnerID=8YFLogxK

U2 - 10.2174/157489012799362412

DO - 10.2174/157489012799362412

M3 - Article

C2 - 22044304

AN - SCOPUS:84857712697

VL - 7

SP - 42

EP - 52

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 1

ER -